Arcutis Biotherapeutics
ARQT
106 hedge funds and large institutions have $895M invested in Arcutis Biotherapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 31 increasing their positions, 29 reducing their positions, and 8 closing their positions.
547% more call options, than puts
Call options by funds: $2.88M | Put options by funds: $445K
175% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 8
14% more funds holding
Funds holding: 93 → 106 (+13)
3.7% more ownership
Funds ownership: 92.19% → 95.89% (+3.7%)
7% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 29
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less capital invested
Capital invested by funds: $925M → $895M (-$29.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$21.1M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$15.1M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$4.37M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.62M |
| 5 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$3.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$175M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.33M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$3.46M |
| 5 |
Citigroup
New York
|
-$1.84M |
ARQT Hedge Fund Activity: Q1 2022 in Review
106 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q1 2022, worth a combined $895M — down 3.1% from $925M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ARQT positions and 8 closed out — a net gain of 14 holders — while 31 added to existing stakes and 29 trimmed.
The largest buyer was Logos Global Management, adding an estimated $21.1M. The largest seller was Frazier Management, exiting entirely with an estimated $175M sold.
- 106 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q1 2022, up from 93 in Q4 2021.
- Funds reported $895M of Arcutis Biotherapeutics stock for Q1 2022, down 3.1% quarter-over-quarter.
- 22 funds opened new Arcutis Biotherapeutics positions in Q1 2022 and 8 closed out, a net change of +14 holders.
- The largest Arcutis Biotherapeutics buyer in Q1 2022 was Logos Global Management, an estimated $21.1M added.
- The largest Arcutis Biotherapeutics seller in Q1 2022 was Frazier Management, an estimated $175M sold.
Based on aggregated 13F filings for Q1 2022.